Health Canada Lifts Suspension on Use of Novartis Influenza Vaccines
We are pleased to advise you that Health Canada has lifted its suspension on the use and distribution of the Novartis influenza vaccines Fluad® and Agriflu®.
Health Canada looked at the results of its own testing, conducted a health risk assessment, and reviewed information from its European partners and data submitted by Novartis in making its decision. None of the information reviewed indicated a safety issue.
As such Agriflu®, Fluad® (Novartis) can be used again as part of our Universal Influenza Immunization Program effective immediately, in addition to the vaccines that you have already been using - Vaxigrip® (Sanofi Pasteur) and Fluviral® (GlaxoSmithKline). Health Canada would also like to remind all vaccine delivery agents that directions pertaining to the use of all influenza vaccine products, as per the product monograph, be followed. These include inspection of the vaccine vial and shaking prior to use.
I have attached, for your information, Health Canada’s statement, key messages and Qs&As as well as my statement that will be issued.
Thank you for your support during the past few days, and for your ongoing partnership in the delivery of our seasonal influenza immunization program. Influenza immunization is the safest and most effective way to protect ourselves, our families and our communities again influenza and its complications.